Result of Retail Offer

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

e-therapeutics plc

("e-therapeutics" or the "Company")

Result of Retail Offer

e-therapeutics plc announced a fundraising on 7 July 2020 comprising a firm placing by Numis Securities Limited (the "Firm Placing"), an associated broker option in the event of additional demand (the "Broker Option"), direct subscriptions with the Company by individual investors based in various overseas jurisdictions (the "Subscription"), and an offer via PrimaryBid (the "Retail Offer"), (together the "Fundraise").

The Company is pleased to announce that the Retail Offer successfully completed and closed at 7.15 p.m. on 7 July 2020.

Following the successful closing of the Retail Offer, the Company has raised gross proceeds of £750,000 at 12 pence per ordinary share through the Retail Offer.

The Company will therefore issue and allot a total of 6,250,000 new ordinary shares of 0.1 pence each (the "Retail Shares") to subscribers pursuant to the Retail Offer.

Application will be made for the Retail Shares, which will rank pari passu with the Company's existing ordinary shares of 0.1 penny each (the "Ordinary Shares"), to be admitted to trading on AIM ("Admission"). Dealings are expected to commence at 8.00 a.m. on 15 July 2020. 

Total Voting Rights

Following the issue of the Retail Shares, the Company will have 404,945,446 Ordinary Shares of 0.1 pence each in issue. The figure of 404,945,446 may be used by the Company's shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Defined terms in this announcement shall have the same meaning as in the Company announcement of 7 July 2020, unless otherwise specified.

Enquiries

e-therapeutics plc +44 (0)1993 883 125

Ali Mortazavi, Executive Chairman www.etherapeutics.co.uk

Laura Roca-Alonso, Chief Business Officer

PrimaryBid Limited +44 20 3026 4750

James Deal